BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Łukawska E, Polcyn-adamczak M, Niemir ZI. The role of the alternative pathway of complement activation in glomerular diseases. Clin Exp Med 2018;18:297-318. [DOI: 10.1007/s10238-018-0491-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Olivos-García A, Nequiz M, Liceaga S, Mendoza E, Zúñiga P, Cortes A, López-Velázquez G, Enríquez-Flores S, Saavedra E, Pérez-Tamayo R. Complement is a rat natural resistance factor to amoebic liver infection. Biosci Rep 2018;38:BSR20180713. [PMID: 30201693 DOI: 10.1042/BSR20180713] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Mao X, Zhou L, Tey SK, Ma APY, Yeung CLS, Ng TH, Wong SWK, Liu BHM, Fung YME, Patz EF Jr, Cao P, Gao Y, Yam JWP. Tumour extracellular vesicle-derived Complement Factor H promotes tumorigenesis and metastasis by inhibiting complement-dependent cytotoxicity of tumour cells. J Extracell Vesicles 2020;10:e12031. [PMID: 33708358 DOI: 10.1002/jev2.12031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Ren H, Zhao L, Zou Y, Wang Y, Zhang J, Wu Y, Zhang R, Wang T, Wang J, Zhu Y, Guo R, Xu H, Li L, Cooper ME, Liu F. Association between atherosclerotic cardiovascular diseases risk and renal outcome in patients with type 2 diabetes mellitus. Ren Fail 2021;43:477-87. [PMID: 33685340 DOI: 10.1080/0886022X.2021.1893186] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Yoshida Y, Kato H, Ikeda Y, Nangaku M. Pathogenesis of Atypical Hemolytic Uremic Syndrome. J Atheroscler Thromb 2019;26:99-110. [PMID: 30393246 DOI: 10.5551/jat.RV17026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
5 Koopman JJE, Rennke HG, McMahon GM, Waikar SS, Costenbader KH. Associations between renal deposits of complement factors, disease activity and loss of renal function in lupus nephritis. J Clin Pathol 2021:jclinpath-2021-207788. [PMID: 34969783 DOI: 10.1136/jclinpath-2021-207788] [Reference Citation Analysis]
6 Lo MW, Kemper C, Woodruff TM. COVID-19: Complement, Coagulation, and Collateral Damage. J Immunol 2020;205:1488-95. [PMID: 32699160 DOI: 10.4049/jimmunol.2000644] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 22.0] [Reference Citation Analysis]
7 Ghosh S, Das S, Mukherjee J, Abdullah S, Mondal R, Sultana S, Sehgal A, Behl T. Enumerating the role of properdin in the pathogenesis of IgA nephropathy and its possible therapies. Int Immunopharmacol 2021;93:107429. [PMID: 33571820 DOI: 10.1016/j.intimp.2021.107429] [Reference Citation Analysis]
8 Fernandez-Ruiz R, Blank RB, Wu M, Belmont HM. C3 glomerulonephritis and systemic lupus erythematosus: A report of a patient treated with eculizumab and review of the literature. Lupus 2021;:9612033211027938. [PMID: 34192954 DOI: 10.1177/09612033211027938] [Reference Citation Analysis]
9 Basnayake BMDB, Wazil AWM, Nanayakkara N, Samarakoon SMDK, Senavirathne EMSK, Thangarajah BUEWDR, Karunasena N, Mahanama RMBSS. Atypical hemolytic uremic syndrome: a case report. J Med Case Rep 2020;14:11. [PMID: 31928535 DOI: 10.1186/s13256-019-2334-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Lo MW, Woodruff TM. Complement: Bridging the innate and adaptive immune systems in sterile inflammation. J Leukoc Biol 2020;108:339-51. [PMID: 32182389 DOI: 10.1002/JLB.3MIR0220-270R] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
11 Dekkers G, Brouwer MC, Jeremiasse J, Kamp A, Biggs RM, van Mierlo G, Lauder S, Katti S, Kuijpers TW, Rispens T, Jongerius I. Unraveling the Effect of a Potentiating Anti-Factor H Antibody on Atypical Hemolytic Uremic Syndrome-Associated Factor H Variants. J Immunol 2020;205:1778-86. [PMID: 32848031 DOI: 10.4049/jimmunol.2000368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Tsiftsoglou SA. SARS-CoV-2 associated Complement genetic variants possibly deregulate the activation of the Alternative pathway affecting the severity of infection. Mol Immunol 2021;135:421-5. [PMID: 33838929 DOI: 10.1016/j.molimm.2021.03.021] [Reference Citation Analysis]
13 Ahmad SB, Bomback AS. C3 Glomerulopathy: Pathogenesis and Treatment. Adv Chronic Kidney Dis 2020;27:104-10. [PMID: 32553242 DOI: 10.1053/j.ackd.2019.12.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
14 Andrighetto S, Leventhal J, Zaza G, Cravedi P. Complement and Complement Targeting Therapies in Glomerular Diseases. Int J Mol Sci 2019;20:E6336. [PMID: 31888179 DOI: 10.3390/ijms20246336] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
15 Mainolfi N, Ehara T, Karki RG, Anderson K, Mac Sweeney A, Liao SM, Argikar UA, Jendza K, Zhang C, Powers J, Klosowski DW, Crowley M, Kawanami T, Ding J, April M, Forster C, Serrano-Wu M, Capparelli M, Ramqaj R, Solovay C, Cumin F, Smith TM, Ferrara L, Lee W, Long D, Prentiss M, De Erkenez A, Yang L, Liu F, Sellner H, Sirockin F, Valeur E, Erbel P, Ostermeier D, Ramage P, Gerhartz B, Schubart A, Flohr S, Gradoux N, Feifel R, Vogg B, Wiesmann C, Maibaum J, Eder J, Sedrani R, Harrison RA, Mogi M, Jaffee BD, Adams CM. Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. J Med Chem 2020;63:5697-722. [PMID: 32073845 DOI: 10.1021/acs.jmedchem.9b01870] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
16 Aounallah H, Bensaoud C, M'ghirbi Y, Faria F, Chmelar JI, Kotsyfakis M. Tick Salivary Compounds for Targeted Immunomodulatory Therapy. Front Immunol 2020;11:583845. [PMID: 33072132 DOI: 10.3389/fimmu.2020.583845] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
17 Schubart A, Anderson K, Mainolfi N, Sellner H, Ehara T, Adams CM, Mac Sweeney A, Liao SM, Crowley M, Littlewood-Evans A, Sarret S, Wieczorek G, Perrot L, Dubost V, Flandre T, Zhang Y, Smith RJH, Risitano AM, Karki RG, Zhang C, Valeur E, Sirockin F, Gerhartz B, Erbel P, Hughes N, Smith TM, Cumin F, Argikar UA, Haraldsson B, Mogi M, Sedrani R, Wiesmann C, Jaffee B, Maibaum J, Flohr S, Harrison R, Eder J. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A 2019;116:7926-31. [PMID: 30926668 DOI: 10.1073/pnas.1820892116] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
18 Ibrahim ST, Chinnadurai R, Ali I, Payne D, Rice GI, Newman WG, Algohary E, Adam AG, Kalra PA. Genetic polymorphism in C3 is associated with progression in chronic kidney disease (CKD) patients with IgA nephropathy but not in other causes of CKD. PLoS One 2020;15:e0228101. [PMID: 32004338 DOI: 10.1371/journal.pone.0228101] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Atosuo J, Karhuvaara O, Suominen E, Vilén L, Nuutila J, Putus T. Indoor-related microbe damage induces complement system activation in building users. Innate Immun 2021;27:15-22. [PMID: 33287602 DOI: 10.1177/1753425920966641] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Tian R, Wang L, Chen A, Huang L, Liang X, Wang R, Mao W, Xu P, Bao K. Sanqi oral solution ameliorates renal damage and restores podocyte injury in experimental membranous nephropathy via suppression of NFκB. Biomedicine & Pharmacotherapy 2019;115:108904. [DOI: 10.1016/j.biopha.2019.108904] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
21 Shi Y, Yao W, Sun L, Li G, Liu H, Ding P, Hu W, Xu H. The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice. BMC Nephrol 2019;20:424. [PMID: 31752725 DOI: 10.1186/s12882-019-1599-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Ahmed MM, Tazyeen S, Ali R, Alam A, Imam N, Malik MZ, Ali S, Ishrat R. Network centrality approaches used to uncover and classify most influential nodes with their related miRNAs in cardiovascular diseases. Gene Reports 2022;27:101555. [DOI: 10.1016/j.genrep.2022.101555] [Reference Citation Analysis]
23 Wang W, Sheng L, Chen Y, Li Z, Wu H, Ma J, Zhang D, Chen X, Zhang S. Total coumarin derivates from Hydrangea paniculata attenuate renal injuries in cationized-BSA induced membranous nephropathy by inhibiting complement activation and interleukin 10-mediated interstitial fibrosis. Phytomedicine 2021;96:153886. [PMID: 35026512 DOI: 10.1016/j.phymed.2021.153886] [Reference Citation Analysis]